LONDON, April 9, 2014 /PRNewswire/ --
On Tuesday, April 08, 2014, the US
markets saw a positive sentiment, with the NASDAQ Composite closing
at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the
session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38%
higher to finish the trading session at 1,851.96. The session saw a
positive impact from Consumer Discretionary, Energy and Utilities
sectors along with a drag from Health Care, Industrials and
Telecommunication Services sectors. A number of stocks saw large
movements, including BioScrip Inc. (NASDAQ: BIOS), E-House China
Holdings Ltd (NYSE: EJ), MagneGas Corp. (NASDAQ: MNGA) and Idera
Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on
BIOS, EJ, MNGA and IDRA can be downloaded upon signing up at:
http://www.investor-edge.com/954-register
BioScrip Inc.'s stock edged 5.81% higher, finishing Tuesday's
session at $7.19. The stock
fluctuated between $7.02 and $7.44
during the session with a trading volume of 3.47 million shares as
compared with its three months average volume of 1.76 million
shares. BioScrip Inc.'s shares have declined 2.31% in the previous
three months and 2.84% on YTD basis. The S&P 500 Health Care
Sector Index mapped a loss of 0.80% during the trading session,
while the same has charted up 1.47% in the previous three months.
BioScrip Inc.'s stock is trading below its 50-day and 200-day
moving averages of $7.68 and
$9.68, respectively. Furthermore, the
company's stock has a Relative Strength Index (RSI) of 40.06. Sign
up today to read free research on BIOS at:
http://www.investor-edge.com/954-BIOS-09Apr2014.pdf
Shares in E-House China Holdings Ltd finished Tuesday's session at
$11.48, up 9.33%. A total of 3.09
million shares were traded which is above its three months average
volume of 2.60 million shares. The stock vacillated between
$10.19 and $11.50 during the session.
Shares in E-House China Holdings Ltd have lost 24.62% in the last
one month and 23.87% on YTD basis. The S&P 500 Financials
Sector Index mapped a gain of 0.13% during the trading session,
while the same has fallen by 2.05% in the last one month.
Additionally, the company's stock has an RSI of 30.60 and is
trading above its 200-day moving average of $9.95. Sign up today to read free research on EJ
at:
http://www.investor-edge.com/954-EJ-09Apr2014.pdf
On Tuesday, shares in MagneGas Corp. ended the session at
$1.55, up 8.39%, with a trading
volume of 2.51 million shares as compared with its three months
average volume of 2.71 million shares. During the session, the
stock traded between $1.42 and $1.60.
MagneGas Corp.'s shares have rallied 104.18% in the last one month,
53.47% in the previous three months, and 252.27% on YTD basis. The
S&P 500 Industrials Sector Index mapped a loss of 0.01% during
the trading session and has declined 1.94% in the last one month.
Further, the company's stock has an RSI of 52.71 and is trading
above its 50-day and 200-day moving averages of $1.06 and $0.79,
respectively. Sign up today to read free research on MNGA at:
http://www.investor-edge.com/954-MNGA-09Apr2014.pdf
Shares in Idera Pharmaceuticals Inc. closed Tuesday's session at
$3.77, up 4.14%, after oscillating
between $3.65 and $3.85. A total of
2.21 million shares were traded, which is below its three months
average volume of 3.68 million shares. Shares in Idera
Pharmaceuticals Inc. have declined 34.78% in the last one month and
18.57% on YTD basis. The S&P 500 Health Care Sector Index
mapped a loss of 0.80% during the trading session and 4.04% in the
last one month. Moreover, the company's stock has an RSI of 34.32
and is trading above its 200-day moving average of $2.91. On April 7,
2014, the company presented new preclinical data
demonstrating the ability of its Toll-like receptor (TLR)
antagonist, IMO-8400. These data add to the growing body of
research which supports the Company's efforts to develop IMO-8400
for the treatment of genetically defined forms of B-cell lymphoma.
Sign up today to read free research on IDRA at:
http://www.investor-edge.com/954-IDRA-09Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
Investor-Edge.com
SOURCE Investor-Edge